Envestnet Asset Management Inc. Acquires 7,204 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Envestnet Asset Management Inc. raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 425,419 shares of the biopharmaceutical company’s stock after buying an additional 7,204 shares during the period. Envestnet Asset Management Inc.’s holdings in Amicus Therapeutics were worth $4,007,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. R Squared Ltd acquired a new position in shares of Amicus Therapeutics during the 4th quarter valued at about $79,000. KBC Group NV lifted its stake in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 3,120 shares during the last quarter. Sciencast Management LP acquired a new stake in shares of Amicus Therapeutics in the fourth quarter worth $100,000. Stephens Inc. AR bought a new stake in shares of Amicus Therapeutics during the 4th quarter worth $101,000. Finally, AlphaQuest LLC grew its stake in Amicus Therapeutics by 635.1% in the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 9,272 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Wells Fargo & Company dropped their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $7.09 on Thursday. The firm has a 50 day moving average of $8.26 and a 200-day moving average of $9.44. Amicus Therapeutics, Inc. has a 1 year low of $6.20 and a 1 year high of $12.65. The stock has a market capitalization of $2.18 billion, a P/E ratio of -39.37, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.